Transfusion Medicine Unit, Hospital Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia; Haematology department, Health Campus, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.
Transfusion Medicine Unit, Hospital Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia; Haematology department, Health Campus, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.
Transfus Clin Biol. 2022 Aug;29(3):224-230. doi: 10.1016/j.tracli.2022.04.001. Epub 2022 Apr 25.
The cryopreservation process of stem cells potentially cause the loss of CD34+ cells. The aim of this study is to evaluate association of patient, graft and technical characteristics with post cryopreserved CD34+ cells viability among lymphoproliferative disease namely multiple myeloma (MM) and lymphoma patients at Hospital Universiti Sains Malaysia (USM). This retrospective study was conducted in the Transplant Unit. A search of the hospital data (2008-2018) to identify 132 patients for both MM and lymphoma who underwent autologous peripheral blood haematopoietic stem cells (APBSC) mobilisation, and were successfully harvested and cryopreserved. Selected patients' profile as well as selected parameters of stem cell mobilization and cryopreservation were obtained from laboratory information system (LIS), record unit and the Transplant Unit. Multiple logistic regression (MLR) was used to find significant associated factors and P<0.05 was considered significant. The mean age of the patients was 39 years old with almost equal gender distribution and majority were lymphoma patients, 96 (72.7%) while 36 (27.3%) were multiple myeloma (MM) patients. The significant influencing factors of post-cryopreserved CD34+ cells viability were pre-cryopreserved CD34+ cell viability, total nucleated cells (TNC), and anti-platelet and antibiotics usage. Patients who are not on anti-platelet and have higher pre-cryopreserved CD34+ cells viability have higher chance for good post-cryopreserved CD34+ cells viability. While, those patients with higher TNC and on antibiotics have lower chance for good post cryopreserved CD34+ cells viability. This study showed patients who are not on anti-platelet and antibiotics will have higher probability of achieving good post cryopreserved CD34+ cells viability. The APBSC products with higher pre-cryopreserved CD34+ cells viability and lower TNC will achieve better post-cryopreserved CD34+ cells viability. The addition of extra plasma to the APBSC products is recommended to reduce the TNC.
干细胞的冷冻保存过程可能导致 CD34+ 细胞的损失。本研究旨在评估患者、移植物和技术特征与多发性骨髓瘤（MM）和淋巴瘤患者在马来西亚大学医院（USM）接受自体外周血造血干细胞（APBSC）动员后冷冻保存的 CD34+ 细胞活力之间的关系。这项回顾性研究在移植科进行。通过检索医院数据（2008-2018 年），确定了 132 名 MM 和淋巴瘤患者，这些患者均接受了自体外周血造血干细胞动员，并成功采集和冷冻保存。从实验室信息系统（LIS）、记录单元和移植科获得选定患者的特征以及干细胞动员和冷冻保存的选定参数。使用多变量逻辑回归（MLR）来寻找显著相关因素，P<0.05 被认为具有统计学意义。患者的平均年龄为 39 岁，性别分布几乎相等，大多数是淋巴瘤患者，96 例（72.7%），36 例（27.3%）为多发性骨髓瘤（MM）患者。冷冻保存后 CD34+ 细胞活力的显著影响因素是冷冻保存前 CD34+ 细胞活力、总核细胞（TNC）以及抗血小板和抗生素的使用。未使用抗血小板药物且冷冻保存前 CD34+ 细胞活力较高的患者，冷冻保存后 CD34+ 细胞活力良好的可能性较高。而那些 TNC 较高且使用抗生素的患者，冷冻保存后 CD34+ 细胞活力良好的可能性较低。本研究表明，未使用抗血小板和抗生素的患者冷冻保存后 CD34+ 细胞活力良好的可能性较高。冷冻保存前 CD34+ 细胞活力较高、TNC 较低的 APBSC 产品将获得更好的冷冻保存后 CD34+ 细胞活力。建议向 APBSC 产品中添加额外的血浆以降低 TNC。
